What does Mounjaro weight loss look like after 6 weeks?

Six weeks covers the starter and first titration phase; the 2.5mg dose is calibrated for your body to adjust, not for maximum effect.
SURMOUNT-1 showed average weight loss of around 20–21% at 15mg over 72 weeks, early results are a fraction of the eventual picture.
Appetite suppression often appears before the scales move, and non-scale changes (looser clothing, reduced hunger) are meaningful signs the medicine is working.
If you have seen little movement by six weeks, that is common at this dose stage and does not indicate the treatment has failed.

Six weeks into Mounjaro, most people are still on the 2.5mg starter dose or have just moved to 5mg — and average weight loss at this stage typically sits in the range of 2–5% of body weight, though individual variation is wide. That figure comes from the SURMOUNT-1 trial data published in the New England Journal of Medicine, which tracked thousands of adults over 72 weeks; the six-week point is early. These are prescription-only medicines, and what happens in your first six weeks depends heavily on dose, adherence, diet, activity and your own biology — a prescriber, not a timeline, is the right guide for interpreting your progress.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

Reading your six-week results honestly and knowing what comes next

Why is weight loss at six weeks usually modest?

The first pen of Mounjaro contains 2.5mg tirzepatide. Clinicians prescribe it at that strength deliberately: it gives the gut-hormone receptors time to adjust and keeps nausea manageable. It is not the dose at which most people see their largest results. Many people reach 5mg around week four or five, which means by week six they are barely into their first therapeutic titration step, and our Mounjaro after 4 weeks page explains what that earlier transition looks like before you arrive at the six-week point.

Tirzepatide works by activating both the GIP and GLP-1 receptors involved in appetite signalling and blood-sugar regulation. That dual action is what sets it apart as the only medicine of its kind licensed for weight management in the UK. But the mechanism builds gradually, gastric emptying slows, hunger cues quieten, portion sizes shrink almost without effort. None of that happens overnight, and the clinical evidence reflects a 72-week programme, not a six-week sprint.

A practical point our prescribers raise often: the scales can lag behind real physiological change. Fluid shifts, constipation and cycle timing all influence the number. Appetite suppression that kicks in at week three or four is the medicine doing its job, even if the weight readout feels underwhelming.

How much weight loss is typical at this point in the programme?

Putting an exact figure on week six is tricky, because the trial data is reported at longer intervals (16 weeks, 36 weeks, 72 weeks) rather than at the six-week mark. What the data does show is that by week 16, participants on the higher doses in SURMOUNT-1 had already lost roughly 8–10% of body weight on average. Six weeks is well before that. A realistic range is 2–5% of starting weight, though some people see more and some see less.

One misconception worth setting down gently: many people arrive expecting the weight to drop fastest at the start, as it does with a crash diet. With Mounjaro, the opposite is often true. The early weeks are the settling-in phase; the steeper part of the loss curve tends to come between months two and six as the dose increases. If your first few weeks feel slow, that is the normal shape of this treatment, and if you have not yet seen movement by week three you may find it helpful to read our guide to three weeks on Mounjaro with no weight loss for context on why the early weeks can be quiet.

For more detail on the four-week milestone, the four-week weight loss page covers what to expect at that earlier stage and how it connects to the six-week picture.

What if the scales have barely moved after six weeks?

This comes up regularly, and it has its own dedicated answer on our six weeks on Mounjaro with no weight loss page. The short version: at 2.5mg, meaningful weight loss is not guaranteed, and the clinical guidance on NICE's tirzepatide appraisal (TA1026) only suggests reviewing whether to continue if there has been less than 5% loss after six months at the highest tolerated dose, not after six weeks at the starting dose.

Practically, the most useful thing to do at the six-week mark is to note non-scale evidence: are you eating less without trying? Are you stopping sooner at meals? Are clothes fitting differently? These point to the medicine working at a biological level even when the number on the scale is moving slowly. Keep a brief log and raise it with your prescriber at the next review.

Dietary habits matter too. Tirzepatide reduces appetite but does not override a high-calorie diet entirely. Protein intake, hydration and moving more all support what the medicine is doing. Personal nutrition targets should be set with your prescriber or a dietitian rather than guessed at.

What should you ask your prescriber after six weeks?

The review conversation at or around the six-week point is worth preparing for. Questions that tend to matter: Is a dose increase appropriate now? Are any side effects worth managing differently? Is the current trajectory in line with expectations, or does the plan need adjusting?

Side effects in the first six weeks are usually gastrointestinal (nausea, loose stools, constipation, some reflux) and mostly settle within days to two weeks of a dose change. Staying hydrated and eating smaller meals helps. If symptoms feel severe or persistent, your prescriber and the Patient Information Leaflet are the right references; the Mounjaro overview page also covers the side-effect profile in more detail.

At nume, every repeat order is reviewed by a GPhC-registered prescriber before it goes out. There are no automatic renewals and no algorithm making dosing calls. If you are unsure whether your six-week picture looks right, that review conversation is exactly what it is there for. You can also explore the wider context of weight loss treatment options if you want to understand where Mounjaro fits in the broader landscape, or look at Mounjaro cost to understand what private treatment involves financially before you decide anything.

Ready to find out whether you are clinically suitable? Check your eligibility with a free consultation, reviewed the same day by a real prescriber.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions